Mice lacking E2F1, E2F2 or E2F3 survive to mid gestation without global defects in the cell cycle, suggesting that the activators are not essential for normal mammalian cell proliferation.

Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I June 11, 2025 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

The completion of Solid Power’s SP2 line by mid-2026 will double electrolyte capacity. Read why I see SLDP stock is well ...

We know so much about the theft of its plans, and its final destruction over the Yavin system—but building the Death Star was ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...

Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential ...